Immunosuppressive and postoperative effects of orthotopic liver transplantation on bone metabolism

Liver Transplantation

Volumn 10, Issue 5, 2004, Pages 638-647

  Guichelaar, Maureen M J ^a,b   Malinchoc, Michael ^a   Sibonga, Jean ^a   Clarke, Bart L ^a   Hay, J Eileen ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CALCITONIN; CALCIUM; CYCLOSPORIN A; METHYLPREDNISOLONE SODIUM SUCCINATE; OKT 3; PREDNISONE; STEROID; TACROLIMUS; VITAMIN D; CYCLOSPORIN; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; BONE BIOPSY; BONE MASS; BONE METABOLISM; CALCIUM BALANCE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; FRACTURE; GONAD FUNCTION; GRAFT REJECTION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INTRAHEPATIC CHOLESTASIS; LIVER FUNCTION; LIVER TRANSPLANTATION; MALE; MORPHOMETRICS; OSSIFICATION; OSTEOLYSIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECIPIENT; BONE; BONE DENSITY; DRUG EFFECT; IMMUNOLOGY; LUMBAR VERTEBRA; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

BONE AND BONES; BONE DENSITY; BONE RESORPTION; CYCLOSPORINE; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; PREDNISONE; TACROLIMUS;

EID: 2442425472     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.20160     Document Type: Article

References (35)

1. Porayko MK, Wiesner RH, Hay JE, et al. Bone disease in liver transplant recipients: incidence, timing, and risk factors. Transplant Proc 1991;23:1462-1465.
2. Meys E, Fontanges E, Fourcade N, Thomasson A, Pouyet M, Delmas PD. Bone loss after orthotopic liver transplantation. Am J Med 1994;97:445-450.
3. Haagsma EB, Thijn CJ, Post JG, Slooff MJ, Gips CH. Bone disease after orthotopic liver transplantation. J Hepatol 1998;6:94-100.
4. Guichelaar MMJ, Malinchoc M, Sibonga J, Clarke BL, Hay JE. Bone histomorphometric changes following liver transplantation for chronic cholestatic liver disease. J Bone Miner Res. 2003;18: 2190-2199.
5. Wiesner RH, LaRusso NF. Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology 1980;79:200-206.
6. Dickson ER, Fleming CR, Ludwig J. Primary biliary cirrhosis. Progress In Liver Disease 1979;6:487-502.
7. Dickson ER, LaRusso NF, Wiesner RH. Primary sclerosing cholangitis. Hepatology 1984;4:33S-35S.
8. Hay JE, Malinchoc M, Dickson ER. A controlled trial of calcitonin therapy for the prevention of post-liver transplantation atraumatic fractures in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 2001;34:292-298.
9. Karnofsky DA, Ableman WH, Craver LF. The use of the nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948;1:634-656.
10. Delmas PD, Stenner D. Increase in serum bone y-carboxyglutamic acid protein with aging in women. J Clin Invest 1983;71: 1316-1321.
11. Kivirikko KI, Laitinen O, Prockop DJ. Modification of a specific assay for hydroxyproline in urine. Annal Biochem 1967;19:249-255.
12. Biddingmeyer BA, Tarvin TL. Rapid analysis of amino acids using precolumn derivation. J of Chromatography 1984;336: 93-104.
13. Kao PC, Heser DW. Simultaneous determination of 26-hydroxy and 1.25-dihydroxyvitamin D from a single sample of dual cartridge extraction. Clin Chem 1984;30:56-61.
14. Woodhead JS. The measurement of circulating parathyroid hormone. Clin Biochem 1990;23:17-21.
15. Hodgson SF, Johnson KA, Muhs JM, Lufkin EG, McCarthy JT. Outpatient percutaneous biopsy of the iliac crest: methods, morbidity, and patients acceptance. Mayo Clin Proc 1986;61:28-33.
16. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols and units. Report of the ASBMR histomorphometry nomenclature committee. J Bone Miner Res 1987;2:595-609.
17. Clarke BL, Ebeling PR, Jones JD, et al. Changes in quantitative bone histomorphometry in aging healthy men. J Clin Endocrinol Metab 1996:81:2264-2270.
18. SAS institute SAS User's Guide, Volume 1. Cary, North Carolina: SAS Institute, 1989.
19. Canalis E, Delany AM. Mechanisms of glucocorticoid action in bone. Annals of the New York Academy of Sciences 2002;966: 73-81.
20. Weinstein RS. Glucocorticoid-induced osteoporosis. Rev Endocr Metab Disord 2001; 2:65-73.
21. Cvetkovic M, Mann GN, Romero DF, et al. The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo. Transplantation 1994;57: 1231-1237.
22. Park KM, Hay JE, Lee SG, et al. Bone loss after orthotopic liver transplantation: FK 506 versus cyclosporine. Transplant Proc 1996;28:1738-1740.
23. Katz IA, Takizawa M, Jaffe II, Stein B, Fallon MD, Epstein S. Comparison of the effects of FK506 and cyclosporine on bone mineral metabolism in the rat. A pilot study. Transplantation 1991;52:571-574.
24. Yoshikawa T, Nakajima H, Yamada E, et al. In vivo osteogenic capability of cultured allogeneic bone in porous hydroxyapatite: immunosuppressive and osteogenic potential of FK506 in vivo. J Bone Miner Res 2000;15:1147-1157.
25. Inoue T, Kawamura I, Matsuo M, et al. Lesser reduction in bone mineral density by the immunosuppressant FK506 compared with cyclosporine in rats. Transplantation 2000;70:774-779.
26. Monegal A, Navasa M, Guanabens N, et al. Bone disease after liver transplantation; a long-term prospective study of changes, hormonal status and histomorphometric characteristics. Osteoporos Int 2001;12:484-492.
27. Favus MJ, Kimberg DV, Miller GN, Gershon E. Effect of cortisone treatment on the active transport of calcium by the small intestines. J Clin Invest 1971;50:1309-1321.
28. Suzuki Y, Ichikawa Y, Saito E, Homma M. Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism 1983;32:151-156.
29. Compston JE, Greer S, Skingle SJ, et al. Early increase in plasma parathyroid hormone levels following liver transplantation. J Hepatol 1996;25:715-718.
30. Janes CH, Dickson R, Okazaki R, McDonagh AF, Riggs BL. Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest 1995;95:2581-2586.
31. Bannister P, Handley T, Chapman C, Losowsky MS. Hypogonadism in chronic liver disease: impaired release of luteinising hormone. BMJ 1986; 293:1191-1193.
32. Galvao-Teles A, Monteiro, E, Gavaler JS, Van Thiel DH. Gonadal consequences of alcohol abuse: lessons from the liver. Hepatology 1986; 6:135-140.
33. Monegal A, Navasa M, Guanabens N, et al. Bone mass and mineral metabolism in liver transplant recipients treated with FK506 or cyclosporine A. Calcif Tissue Int 2001; 68:83-86.
34. Guanabens N, Pares A, Alvarez L, et al. Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis. J Bone Miner Res 1998;13:731-738.
35. Guichelaar MMJ, Malinchoc M, Sibonga J, Clarke BL, Hay JE. Bone metabolism in advanced cholestatic liver disease: analysis by bone histomorphometry. Hepatology 2002; 36:895-903.